166 J ournal of Medicinal Chemistry, 2000, Vol. 43, No. 2
O’Brien et al.
(16) Holman, C.; Kan, C. C.; Gehring, M.; Van Wart, H. Role of His-
224 in the Anomolous pH Dependence of Human Stromelysin-
1. Biochemistry 1999, 38, 677-681.
(17) J ohnson, L. L.; Pavlovsky, A. G.; J ohnson, A. R.; Hupe, D. J .;
J anowicz, J . A.; Man, C.-F.; Ortwine, D. F.; Purchase, C. F., III;
White, A. D. A Rationalization of the Acidic pH Dependence for
Stromelysin-1 (MMP-3) Catalysis and Inhibition. J . Biol. Chem.,
submitted.
(18) J ohnson, L.; Bornemeier, D.; J anowicz, J .; Chen, J .; Pavlovsky,
A.; Ortwine, D. Effect of Species Differences on Stromelysin-1
(MMP-3) Inhibitor Potency: An Explanation of Inhibitor Selec-
tivity Using Homology Modeling and Chimeric Proteins. J . Biol.
Chem. 1999, 274, 24881-24887.
(19) Parker, M. H.; Lunney, E. A.; Ortwine, D. F.; Pavlovsky, A. G.;
Humblet, C.; Brouillette, C. G. Analysis of the Binding of
Hydroxamic Acid and Carboxylic Acid Inhibitors to the Stromel-
ysin-1 (Matrix Metalloproteinase-3) Catalytic Domain by Iso-
thermal Titration Calorimetry. Biochemistry 1999, 38, 13592-
13601.
(20) Dhanaraj, V.; Ye, Qui-Zhuang; J ohnson, L. L.; Hupe, D. J .;
Ortwine, D. F.; Dunbar, J . B., J r; Rubin, J . R.; Pavlovsky, A.;
Humblet, C.; Blundell, T. L. X-ray Structure of a Hydroxamate
Inhibitor Complex of Stromelysin Catalytic Domain and its
Comparison with Members of the Zinc Metalloproteinase Su-
perfamily. Structure 1996, 4, 375-386.
(21) Massova, I.; Fridman, R.; Mobashery, S. Structural Insights into
the Catalytic Domains of Human Matrix Metalloprotease-2 and
Human Matrix Metalloprotease-9: Implications for Substrate
Specificities. J . Mol. Model. [Electronic Publication] 1997, 3, 17-
30.
(22) Lovejoy, B.; Welch, A. R.; Carr, S.; Luong, C.; Broka, C.;
Hendricks, R. T.; Campbell, J . A.; Walker, K.; Martin, R.; Van
Wart, H.; Browner, M. Crystal Structures of MMP-1 and MMP-
13 Reveal the Structural Basis for Selectivity of Collagenase
Inhibitors. Struct. Biol. 1999, 6, 217-221.
(23) Ye, Q. Z.; J ohnson, L.; Hupe, D. J .; Baragi, V. Purification and
Characterization of the Human Sromelysin Catalytic Domain
Expressed in Escherichia coli. Biochemistry 1992, 31, 11231-
11235.
Ack n ow led gm en t. We thank Dr. G. A. McClusky
and staff for spectral and analytical determinations. We
are also indebted to Ms. B. Leja for developing the chiral
HPLC assay used to determine the enantiomeric puri-
ties of compounds 11c,c′.
Refer en ces
(1) Matrisian, L. M. The Matrix Degrading Proteinases. Bioessays
1992, 14, 455-463.
(2) Denhardt, D. T.; Feng, B.; Edwards, D. R.; Cocuzzi, E. T.;
Malyankar, U. M. Tissue Inhibitor of Metalloproteinases (TIMP,
aka EPA): Structure, Control of Expression and Biological
Function. Pharmacol. Ther. 1993, 59, 329-341.
(3) Firestein, G. S.; Paine, M. M.; Littman, B. H. Gene Expression
(Collagenase, Tissue Inhibitors of Metalloproteinase, Comple-
ment and HLA-DR) in Rheumatoid and Osteoarthritic Syn-
ovium. Arthritis Rheum. 1991, 34, 1094-1105.
(4) Pyke, C.; Ralfkiaer, E.; Huhtala, P.; Hurskainen, T.; Danoe, K.;
Tryggvason, K. Localization of Messenger RNA for Mr 72,000
and 92,000 Type IV Collagenases in Human Skin Cancers by in
situ Hybridization. Cancer Res. 1992, 52, 1336-1341.
(5) Thompson, R.; Parks, W. Role of Matrix Metalloproteinases in
Abdominal Aortic Aneurysms. Ann. NY Acad. Sci. 1996, 800,
157-174.
(6) Thomas, C. V.; Coker, M. L.; Zellner, J . L.; Handy, J . R.;
Crumbly, A. J .; Spinale, F. G. Increased Matrix Metalloprotein-
ase Activity and Selective Upregulation in LV Myocardium from
Patients with End-Stage Dilated Cardiomyopathy. Circulation
1998, 97, 1708-1715.
(7) Nagase, H. Matrix Metalloproteinases. In Zinc Metalloprotein-
ases in Health and Disease; Hooper, N. M., Eds.; Taylor and
Francis: London, 1996; pp 153-204.
(8) (a) Nagase, H. Activation Mechanisms of Matrix Metallopro-
teinases. Biol. Chem. 1997, 378, 151-160. (b) Massova, I.; Kotra,
L. P.; Fridman, R.; Mobashery, S. Matrix Metalloproteinases:
Structures, Evolution, and Diversification. FASEB 1998, 12,
1075-1095.
(9) (a) Babine, E. R.; Bender, S. L. Molecular Recognition of
Protein-Ligand Complexes: Application to Drug Design. Chem.
Rev. 1997, 97, 1359-1472. (b) Shuker, S.; Hajduk, P.; Meadows,
R.; Fesik, S. Discovering High Affinity Ligands for Proteins:
SAR by NMR. Science 1996, 274, 1531-1534.
(10) Beckett, R. P.; Whittaker, M. Matrix Metalloproteinase Inhibi-
tors 1998. Exp. Opin. Ther. Patents 1998, 8, 259-282.
(11) Whittaker, M.; Brown, P. Recent Advances in Matrix Metallo-
proteinase Inhibitor Research and Development. Curr. Opin.
Drug Discuss. 1998, 1, 157-164.
(12) Tamura, Y.; Watanabe, F.; Nakatani, T.; Yasui, K.; Fuji, M.;
Komurasaki, T.; Tsuzuki, H.; Maekawa, R.; Yoshioka, T.;
Kawada, K.; Sugita, K.; Ohtani, M. Highly Selective and Orally
Active Inhibitors of Type IV Collagenase (MMP-9 and MMP-2):
N-Sulfonylamino Acid Derivatives. J . Med. Chem. 1998, 41,
640-649.
(13) Pavlovsky, A.; Ye, Q. Z.; Ortwine, D.; Humblet, C.; Purchase,
C.; White, A.; Roth, B.; J ohnson, L.; Hupe, D.; Williams, M.;
Dhanaraj, V.; Blundell, T. X-ray Structure of Human Stromel-
ysin Catalytic Domain Complexed with Non-Peptide Inhibi-
tors: Implications for Inhibitor Selectivity. Protein Sci. 1999,
8, 1455-1462. Entry 1caq in the Protein Databank.
(14) Miyaura, N.; Yanagi, T.; Suzuki, A. The Palladium-Catalyzed
Cross-Coupling Reaction of Phenylboronic Acid with Haloarenes
in the Presence of Bases. Synth. Commun. 1981, 11, 513-519.
(15) Wilhelm, S. M.; Shao, Z. H.; Housely, T. J .; Seperack, P. K.;
Baumann, A. P.; Gunja-Smith, Z.; Woessner, J . F. Matrix
Metalloproteinase-3 (Stromelysin-1). Identification as the Car-
tilage Acid Metalloprotease and Effect of pH on Catalytic
Properties and Calcium Affinity. J . Biol. Chem. 1993, 268,
21906-21913.
(24) Harrison, R. K.; Chang, B.; Niedzwiecki, L.; Stein, R. L.
Mechanistic Studies on the Human Matrix Metalloproteinase
Stromelysin. Biochemistry 1992, 31, 10757-10762.
(25) Woessner, J . F.; Gunja-Smith, Z. Role of Metalloproteinases in
Human Osteoarthritis. J . Rheumatol. 1991, 18, 99-101.
(26) Commercially available from Tripos Associates, 1699 S. Hanley
Rd, Suite 303, St. Louis, MO 63144-2913. Version 6.3, operating
on Silicon Graphics workstations, was used for the calculations.
(27) Commercially available from Wavefunction, Inc., 18401 Von
Karman, Suite 370, Irvine, CA 92612. Version 5.1.1, operating
on Silicon Graphics Octane, was used for the calculations.
(28) The IMCA-CAT facilities are supported by the companies of the
Industrial Macromolecular Crystallography Association through
a contract with Illinois Institute of Technology (ITT), executed
through the ITT’s Center for Synchrotron Radiation Research
and Instrumentation. Use of the Advanced Photon Source was
supported by the U.S. Department of Energy, Basic Energy
Sciences, Office of Energy Research, under Contract No. W-31-
109-Eng-38.
(29) Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data
Collected in Oscillation Mode. Methods Enzymol. 1997, 276
(Macromolecular Crystallography, Part A), 307-326.
(30) Navaza, J . AmoRe: An Automated Package for Molecular
Replacement. Acta Crystallogr. 1994, A50, 157-163.
(31) (a) Brunger, A. T.; Kuryan, J .; Karplus, M. Crystallographic
R-Factor Refinement by Molecular Dynamics. Science 1987, 235,
458-460. (b) Brunger, A. T. X-PLOR: A System for X-ray
Crystallography and NMR; Yale University Press: New Haven,
CT, 1992.
J M9903141